The Newer Eczema Biologics Beyond Dupilumab

What Tralokinumab and Lebrikizumab Are

Tralokinumab and lebrikizumab are both injectable biologic medications that target interleukin-13 (IL-13), an inflammatory signaling protein involved in the immune overactivity that drives atopic dermatitis, and both belong to the systemic biologic tier of eczema treatment covered by current dermatology guidelines 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy.. They are self-injected on a regular schedule after an initial training period, the same delivery format used for other biologics in this class.

Interleukin-13 (IL-13) is one signaling protein among several involved in eczema's underlying inflammation, and targeting it specifically is the shared mechanism behind both drugs, even though they come from different manufacturers and aren't interchangeable prescriptions. Neither is a cream, a pill, or a short course — both are ongoing treatments meant to be continued as long as they're working and well tolerated, similar to how other biologics in dermatology are used long-term rather than for a fixed number of weeks.

Where They Fit on the Eczema Treatment Ladder

Eczema treatment generally follows a ladder: moisturizers and gentle skin care first, then topical corticosteroids or topical calcineurin inhibitors, and only after those haven't controlled the disease does a systemic option like a biologic enter the conversation 2Ref 2Sidbury R, Alikhan A, Bercovitch L, et al. (2023).Guidelines of care for the management of atopic dermatitis in adults with topical therapies.First-line topical treatment steps (moisturizers, topical corticosteroids, calcineurin inhibitors) that precede systemic/biologic treatment on the eczema ladder.. Tralokinumab and lebrikizumab sit at that same systemic step, alongside dupilumab and the oral JAK inhibitors, rather than replacing any of the topical steps that come before it 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy..

Oral JAK inhibitors for eczema occupy the same tier but in pill form rather than as an injection, which is one of the practical differences a prescriber and patient weigh together — needle aversion versus a daily pill and its own monitoring requirements are both reasonable factors in that conversation, not a medical judgment one way or the other.

How an IL-13-Specific Biologic Compares to Dupilumab

Dupilumab, the first biologic approved for eczema, was established through large placebo-controlled trials showing clear improvement in skin clearance, itch, and quality of life for adults with moderate-to-severe disease not adequately controlled by topical therapy 3Ref 3Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016).Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.Dupilumab's trial-established efficacy for signs, symptoms, itch, and quality of life in adults with moderate-to-severe atopic dermatitis, as the comparator with the longest track record in this drug class.. Tralokinumab and lebrikizumab arrived several years later, developed to act on the IL-13 signal within that same broader inflammatory pathway, and are addressed within the same class of systemic biologic options current dermatology guidelines cover 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy..

Because both newer drugs are more recent to market, they simply have a shorter real-world track record than dupilumab, whose original trials remain some of the most cited efficacy data in the class 3Ref 3Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016).Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.Dupilumab's trial-established efficacy for signs, symptoms, itch, and quality of life in adults with moderate-to-severe atopic dermatitis, as the comparator with the longest track record in this drug class.. A shorter track record isn't the same as a weaker one — it mostly means less accumulated real-world experience, which is one factor, among several, that a prescriber may weigh.

Why Someone Might Be Offered One Instead of Dupilumab

The choice between dupilumab and a newer IL-13-specific biologic is not usually about one being uniformly stronger than the other — it more often comes down to insurance formulary coverage, how a person responded to or tolerated a prior biologic, and a prescriber's read of the individual case 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy.. Someone whose eczema didn't respond adequately to one option in this class is sometimes tried on another rather than moving straight to a different treatment category entirely.

This is part of why eczema systemic options are best discussed as a group rather than a single default choice: dupilumab vs a JAK inhibitor for eczema is one comparison a prescriber might walk through, and dupilumab vs an IL-13-specific biologic is another, with the right answer depending on a specific person's history rather than a universal ranking.

Part of a Broader Pattern in Immune-Mediated Skin Disease

Eczema's expanding biologic options mirror a pattern already established in psoriasis, where treatment moved from broad TNF inhibitors toward increasingly targeted IL-17 and IL-23 inhibitors as the biologic class matured and more specific inflammatory targets were identified 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.Cross-disease analogy: psoriasis biologic treatment evolving from broad TNF inhibitors toward more targeted IL-17/IL-23 inhibitors, with no single agent uniformly first-choice.. The same trend — narrower, more specific targets supplementing broader ones — is now playing out in eczema treatment as tralokinumab and lebrikizumab join dupilumab in the systemic tier.

Choosing among the psoriasis biologics has followed a similar logic for years: no single agent is uniformly first-choice, and the decision rests on disease pattern, comorbidities, and individual response 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.Cross-disease analogy: psoriasis biologic treatment evolving from broad TNF inhibitors toward more targeted IL-17/IL-23 inhibitors, with no single agent uniformly first-choice.. Eczema's biologic landscape is still younger than psoriasis's, but it appears to be following the same trajectory toward more, and more targeted, options over time.

What Starting One of These Biologics Involves

Starting a biologic for eczema typically involves a discussion of disease severity, prior treatment history, and any relevant health conditions, followed by training on self-injection technique before the first dose is given independently 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy.. Ongoing follow-up tracks how well the skin and itch are responding, since the systemic tier is reserved for disease that topical treatment alone couldn't control.

Most people continue at least some topical care alongside the biologic rather than stopping it entirely, since a biologic addresses the underlying immune signal while moisturizing continues to support the skin barrier itself. Response is usually assessed over a period of months rather than days, and a plan that isn't working is adjusted rather than abandoned outright.

The specific follow-up schedule — how often check-ins happen, what gets reassessed at each one, and how long before a treatment is judged as working or not — is set by the prescribing clinician based on the individual case and the guideline in effect, rather than following a single fixed calendar for everyone on this drug class 1Ref 1Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Systemic/biologic tier of eczema treatment including dupilumab and other biologics, reserved for moderate-to-severe disease not controlled by topical therapy..

The Underlying Condition These Biologics Are Treating

Atopic dermatitis, the clinical term for the eczema these biologics treat, is driven by a combination of immune system overactivity and a skin barrier that doesn't hold onto moisture the way it should, and it often runs alongside other atopic conditions like asthma, food allergy, or allergic rhinitis 5Ref 5National Institute of Allergy and Infectious Diseases (2024).Eczema (Atopic Dermatitis).General definitional background: atopic dermatitis driven by immune dysregulation and skin-barrier dysfunction, associated with the atopic march (asthma, food allergy, allergic rhinitis).. Biologics like tralokinumab and lebrikizumab intervene on the immune-overactivity side of that equation rather than the barrier side.

That division is why moisturizing and gentle skin care remain part of the plan even after someone starts a biologic — the injection and the daily skin-care routine are addressing two different parts of the same condition, not competing approaches.